Spinal Cord Stimulation for Parkinsonism

Launched by RUIJIN HOSPITAL · Dec 9, 2021

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called Spinal Cord Stimulation (SCS) for people with Multiple System Atrophy (MSA), a rare neurological condition. The study aims to see if SCS can help improve some of the tough symptoms faced by MSA patients, such as low blood pressure when standing (orthostatic hypotension), difficulties with urination (urinary retention), trouble sleeping (sleep disturbances), and problems with speaking (dysarthria) and swallowing (dysphagia). By combining insights from previous studies, this trial hopes to offer a fresh approach to managing these symptoms.

To be eligible for this trial, participants must be between the ages of 18 and 80, live in China, and show clear symptoms related to MSA. They should also be willing to maintain their current medications and provide consent for the SCS procedure. Throughout the study, participants can expect to undergo assessments before and after the treatment to measure any improvements in their symptoms. Importantly, the trial is designed to minimize risks and complications, as SCS is known for being a safe and reversible option.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Diagnosed with parkinsonism according to MDS clinical diagnostic criteria for Parkinson's disease
• • 2. Aged between 50 and 80 years
• • 3. Able and willing to follow instruction of the researcher
• • 4. No other conditions that the researchers consider inappropriate for inclusion
• Exclusion criteria:
• • 1. Severe depression (HAMD-17 above 17 as moderate to severe) or anxiety
• • 2. Pregnancy
• • 3. History of alcoholism
• • 4. Non-neurological disease-related symptoms that prevent patients from participation in the study